Fig. 2

Degenerative modifications in MBP. a 3D structural modelling of MBP sequence in AD + CVD, showing modified sites including Arg citrullination and Gln/Asn deamidation. b Stoichiometry of MBP deamidation considering the percentage of all confidentially identified peptides in all groups (AD + CVD subjects and controls). c Relative level of Gln deamidation considering all the identified sites from the obtained iTRAQ peak intentities in age-matched controls, AD + CVD women and AD + CVD men. d Relative levels of Asn deamidation considering all the identified sites from the obtained iTRAQ peak intentisites in age-matched controls, AD + CVD women and AD + CVD men. e Site distribution of Gln deamidation peak intensities in age-matched controls, AD + CVD women and AD + CVD men. f Site distribution of Asn deamidation peak intensities in age-matched controls, AD + CVD women and AD + CVD men. g Stoichiometry of MBP citrullination considering the percentage of all confidentially identified peptides in all groups (AD + CVD subjects and controls). h Relative level of Arg citrullination across all sites based on the obtained iTRAQ areas in age-matched controls, women with dementia, and men with dementia. i Site distribution of Arg citrullination iTRAQ area intentities in MBP from age-matched controls, women with dementia, and men with dementia. Significance level in graphs (* p < 0.05; ** p < 0.001)